A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

NCT00679341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab emtansine [Kadcyla]
DRUG: Trastuzumab
DRUG: Docetaxel

Sponsor

Hoffmann-La Roche